EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Limosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application

Manfei Jin, Fei Xu, Yinhua Liu, Zhao Jiang

Food and Chemical Toxicology · 2026

DOI: 10.1016/j.fct.2026.116002 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Food and Chemical Toxicology, 2026. Verfasst von Manfei Jin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Plateau Biomedical Big Data Mining, and Bioinformatics Analysis Laboratory, Xizang Minzu University, Xianyang, 712082, China; Provincial Key Laborato…. Hauptthemen laut MEDLINE: Limosilactobacillus fermentum, Probiotics. Die Arbeit nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study presents a comprehensive multidimensional assessment of the safety and functional efficacy of Limosilactobacillus fermentum LF61, a strain isolated from human milk. Genomic analysis revealed no virulence factors (VFDB), drug resistance genes (CARD), or toxin synthesis gene cluster (antiSMASH) within its chromosome (2.04 Mb) and plasmid (15.5 kb), meeting EFSA's QPS safety criteria. In vitro studies demonstrated that LF61 exhibited a 2-h survival rate of >98% in gastric acid (pH 2.0) and a survival rate of 99.66% in intestinal fluid (pH 8.0). LF61 was also nontoxic to Caco-2 cells (metabolic activity at 20% concentration: 100.3 ± 2.1%). An acute oral toxicity test (in ICR mice) demonstrated an LD50 > 2 × 1010 CFU/kg. In a randomized, double-blind clinical trial (n = 49), daily intake of 3 × 1010 CFU of LF61 for 8 weeks increased serum levels of the antimicrobial peptide LL-37 by 12.3% (p 3), activated the carbohydrate metabolism pathway (p = 0.002), and maintained stable α-diversity in the microbiome (Shannon index p > 0.05). Collectively, our findings indicate that LF61 exerts beneficial effects via a gut-immune axis bidirectional regulatory mechanism, offering a theoretical basis and clinical evidence for the development of novel immunomodulatory probiotics targeting the gut-immune axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Limosilactobacillus fermentumProbioticsHumansAnimalsMiceGenomicsCaco-2 CellsMice, Inbred ICRFemaleDouble-Blind Method

Stichwörter der Autor:innen

Immune functionIntestinal floraLimosilactobacillus fermentum LF61Safety evaluationWhole genome sequencing

Autor:innen und Institutionen

  • Plateau Biomedical Big Data Mining, and Bioinformatics Analysis Laboratory, Xizang Minzu University, Xianyang, 712082, China; Provincial Key Laboratory of Molecular Genetic Mechanism and Intervention of Diseases Related…
  • College of Food Science and Technology, Henan University of Technology, Zhengzhou, China.
  • College of Food Science and Technology, Henan University of Technology, Zhengzhou, China. Electronic address: liuyh_2023@163.com.

Zitieren

APA

Jin, M., Xu, F., Liu, Y., & Jiang, Z. (2026). Limosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application. Food and Chemical Toxicology. https://doi.org/10.1016/j.fct.2026.116002

Vancouver

Jin M, Xu F, Liu Y, Jiang Z. Limosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application. Food and Chemical Toxicology. 2026. doi:10.1016/j.fct.2026.116002

BibTeX
@article{Jin2026,
  author = {Jin, Manfei and Xu, Fei and Liu, Yinhua and Jiang, Zhao},
  title = {Limosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application},
  journal = {Food and Chemical Toxicology},
  year = {2026},
  doi = {10.1016/j.fct.2026.116002}
}
Kostenlos starten →